August 2025: *As featured in Forbes Magazine [Argentina] In the age of social listening and efficient communication technologies, patient groups have been able to amplify their collective voice, becoming increasingly… Continue reading “Patients and the power of their collective voice”
Agosto 2025: *Según publicación en la revista Forbes [Argentina] En la era de la escucha social y las tecnologías de comunicación eficientes, los grupos de pacientes han podido amplificar su… Continue reading “Industria farmacéutica: los pacientes y el poder de su voz colectiva”
July 2025: The global cancer burden is rising. The fourth edition of The Cancer Atlas, produced by The American Cancer Society (ACS) and the International Agency for Research on Cancer… Continue reading “Insights from cancer patient groups”
June 2025: In recent decades, patient groups have radically transformed their role in the healthcare landscape. Today, thousands of patient advocacy groups are helping to steer research and development, influence… Continue reading “An Introduction to Moving Forward”
May 2025: In April 2025, PatientView released the 14th edition of the Corporate Reputation of Pharma report. This year, the number of pharmaceutical companies in the analyses increased to 46,… Continue reading “Broadening representation – why new companies entered PatientView’s 2024/25 Corporate Reputation of Pharma rankings”
March 2025: PatientView’s ‘Patients in Action’ survey which ran from June to August 2024 attracted responses from 1,144 patient groups (drawn from 83 countries, and from 65 broad specialties). 39… Continue reading “Patients in Action—a focus on breast cancer patient groups”
January 2025: Health Technology Assessments (HTAs) systematically evaluate the properties, impacts, and effects of treatments or medical devices to guide decisions on their adoption, use, or reimbursement. They address medical,… Continue reading “Patient Groups and Health Technology Assessments (HTAs)”
December 2024: A new systematic analysis from PatientView identifying specific strategic steps that pharma needs to take to improve its reputation. PatientView’s annual ‘Corporate Reputation of Pharma’ assesses the performance… Continue reading “How Pharma needs to improve, according to patient groups in Asia-Pacific”
November 2024: Over the past 40 years, the role of patient groups has undergone a radical transformation. Historically, patients—and the groups representing them—had minimal influence on their healthcare systems, frequently… Continue reading “Patients in Action”
July 2024: The field of oncology, cancer research and cancer treatment has seen continued investment over the last few years. In the UK, cancer incidence rates are projected to rise… Continue reading “PatientView’s Corporate Reputation of Pharma 2023/24: Insights from Specialised Cancer Patient Groups”
